Jim Cullen
Cullen Value Fund
Jim Cullen Pfizer Inc stake
total: 74
Cullen Value Fund PFE trades
- Total transactions:
- 7
- New positions:
- 2
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 3
- Held since:
- 2025 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2025 Q4
According to 2026 Q1 report, Jim Cullen holds 21,860 Pfizer Inc (PFE) shares with a market value of roughly $613.83K accounting for 2.16% of the overall portfolio. To date, the estimated cost basis is nearly $24.9 for "buy" trades. Cullen Value Fund first purchased PFE in 2019 Q3, initially acquiring 29,550 shares. Jim Cullen later completely sold out the position and invested in Pfizer Inc again in 2025 Q4. Since the initial investment in Pfizer Inc (PFE), Cullen Value Fund has made 6 more transactions.
When did Jim Cullen buy Pfizer Inc (PFE)?
Jim Cullen first invested in Pfizer Inc (PFE) in 2019 Q3 at the reported quarter-end price of $35.93 per share.
What's the cost basis of Cullen Value Fund's PFE stake?
The estimated cost basis for Pfizer Inc (PFE) stake is around $24.90 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $24.90
Jim Cullen's historical trades in Pfizer Inc
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
1.97%
|
21,860
|
$24.90
|
$544,314
|
new
|
+1.97%
|
|
2025 Q2
|
0.00%
|
0
|
$25.34
|
|
-100% (-14,674)
|
-1.61%
|
|
2023 Q1
|
2.71%
|
14,674
|
$40.80
|
$598,699
|
-26.99% (-5,424)
|
-0.93%
|
|
2022 Q3
|
4.23%
|
20,098
|
$43.76
|
$879,488
|
-8.94% (-1,974)
|
-0.37%
|
|
2020 Q4
|
3.28%
|
$36.81
|
+4.88% (+1,027)
|
|||
|
2019 Q4
|
2.75%
|
$39.18
|
-28.78% (-8,505)
|
|||
|
2019 Q3
|
2.73%
|
$35.93
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.